
Physitrack - Strong Finish to the Year, well positioned for 2025

Physitrack's Q4 2024 report came in stronger on sales than expected but slightly below profitability due to a higher-than-anticipated cost base. Wellness returned to sequential growth, while Lifecare continued its solid performance. Cost efficiencies should support margin expansion, with adjusted EBITDA expected to reach 30% in 2025. Management sees no need for external funding, reinforcing financial stability. Additionally, 2025 appears to be off to a strong start, with positive deal flow and business momentum.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Physitrack - Strong Finish to the Year, well positioned for 2025](#)